QT Imaging and Trimedyne Compared in Critical Review

Analysts examine the performance, valuation, and ownership of these two small-cap medical companies.

Feb. 6, 2026 at 4:39am

Got story updates? Submit your updates here. ›

A critical review compares the performance, valuation, and ownership of two small-cap medical companies, QT Imaging (NASDAQ:QTI) and Trimedyne (OTCMKTS:TMED). The analysis looks at factors like revenue, earnings, volatility, institutional ownership, and more to determine which stock is the superior investment.

Why it matters

This comparison provides investors with an in-depth look at the relative strengths and weaknesses of these two niche medical technology companies, helping them make more informed decisions about where to allocate their capital.

The details

The review finds that QT Imaging has lower volatility but higher valuation, while Trimedyne has higher volatility but lower valuation. Trimedyne has lower revenue but higher earnings than QT Imaging. QT Imaging also has stronger institutional ownership and insider ownership than Trimedyne.

  • The article was published on February 6, 2026.

The players

QT Imaging

A medical technology company that develops and commercializes ultrasonic imaging systems for breast cancer detection and diagnosis.

Trimedyne

A medical device manufacturer that produces lasers, fiber-optic laser devices, and other products for use in various medical specialties.

Got photos? Submit your photos here. ›

The takeaway

This analysis provides a detailed comparison of two small-cap medical technology companies, highlighting their relative strengths and weaknesses across a range of financial and operational metrics. Investors can use this information to better assess the potential risks and rewards of investing in QT Imaging versus Trimedyne.